Survey of International Regulatory Bioequivalence Recommendations for Approval of Generic Topical Dermatological Drug Products
Journal Title: The AAPS Journal - Year 2015, Vol 17, Issue 1
Abstract
The objective of this article is to discuss the similarities and differences in accepted bioequivalence (BE) approaches for generic topical dermatological drug products between international regulatory authorities and organizations. These drug products are locally applied and not intended for systemic absorption. Therefore, the BE approaches which serve as surrogates to establish safety and efficacy for topical dosage forms tend to differ from the traditional solid oral dosage forms. We focused on 15 different international jurisdictions and organizations that currently participate in the International Generic Drug Regulators Pilot Project. These are Australia, Brazil, Canada, China, Chinese Taipei, the European Medicines Association (EMA), Japan, Mexico, New Zealand, Singapore (a member of the Association of Southeast Asian Nations), South Africa, South Korea, Switzerland, the USA and the World Health Organization (WHO). Upon evaluation, we observed that currently only Canada, the EMA, Japan, and the USA have specific guidance documents for topical drug products. Across all jurisdictions and organizations, the three approaches consistently required are (1) BE studies with clinical endpoints for most topical drug products; (2) in vivo pharmacodynamic studies, in particular the vasoconstrictor assay for topical corticosteroids; and (3) waivers from BE study requirements for topical solutions. Japan, South Africa, the USA, and the WHO are also making strides to accept other BE approaches such as in vivo pharmacokinetic studies for BE assessment, in vivo dermatopharmacokinetic studies and/or BE studies with in vitro endpoints.
Authors and Affiliations
April C. Braddy, Barbara M. Davit, Ethan M. Stier, Dale P. Conner
Keywords
Related Articles
- EP ID EP680898
- DOI 10.1208/s12248-014-9679-3
- Views 47
- Downloads 0
Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions
Drug-induced hypersensitivity reactions are instructive examples of immune reactions against low molecular weight compounds. Classically, such reactions have been explained by the hapten concept, according to which the s...
PEG-conjugated PAMAM Dendrimers Mediate Efficient Intramuscular Gene Expression
Generations 5 and 6 (G5 and G6) poly(amidoamine) (PAMAM) dendrimers have been shown to be highly efficient nonviral carriers in in vitro gene delivery. However, their high toxicity and unsatisfied in vivo efficacy limit...
Biodegradable Particles as Vaccine Delivery Systems: Size Matters
Poly(lactide-co-glycolide) (PLGA) particles have strong potential as antigen delivery systems. The size of PLGA particles used to vaccinate mice can affect the magnitude of the antigen-specific immune response stimulated...
Cannabinoid receptors and endocannabinoids: Evidence for new players
It is now well established that the psychoactive effects ofCannabis sativa are primarily mediated through neuronal CB1 receptors, while its therapeutic immune properties are primarily mediated through CB2 receptors. Two...
Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation
The online version of this article (doi:10.1208/s12248-015-9803-z) contains supplementary material, which is available to authorized users.